Novo Nordisk Sues Hims & Hers for Patent Infringement (NVO: +1.2% Pre-Market)

Novo Nordisk (NVO) has filed a lawsuit in the U.S. District Court in Massachusetts against Hims & Hers, alleging infringement of its erectile dysfunction drug Cialis and related formulations. The complaint seeks injunctive relief and damages, citing claims under the Federal Drug Administration's 505(g)(3) Abbreviated New Drug Application and related intellectual property rights. The filing follows a patent dispute dating back to 2021, with Novo Nordisk seeking to block or limit the use of Cialis and its generics by Hims & Hers, which has expanded its telemedicine erectile dysfunction services. The company has not yet provided an estimated range of damages, but the case could have significant implications for generics availability and pricing.